All In Biotech

Drug Trial Radar · NCT04209855

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 453 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

453

Actual

Start

Dec 31, 2019

Primary completion

Mar 6, 2023

Study completion Oct 29, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
Gynecologic Oncology Group; European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
Dec 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. The FRα positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.

Conditions

  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Interventions

  • Mirvetuximab SoravtansineDrug

    Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.

  • PaclitaxelDrug

    Paclitaxel will be administered per dose and schedule specified in the arm.

  • TopotecanDrug

    Topotecan will be administered per dose and schedule specified in the arm.

  • Pegylated liposomal doxorubicinDrug

    Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From randomization until PD or death, whichever occurred first (up to approximately 36 months)

Locations

214 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) GYN Oncology

    Birmingham, Alabama

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Arizona Oncology Associates, PC - HAL - USOR

    Phoenix, Arizona

  • Mayo Clinic

    Phoenix, Arizona

  • USOR: Arizona Oncology Associates, PC - HOPE

    Tucson, Arizona

  • University of Arizona Cancer Center

    Tucson, Arizona

  • UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit

    Los Angeles, California

  • Hoag Cancer Center

    Newport Beach, California

  • University of California San Francisco

    San Francisco, California

  • Olive View - UCLA Medical Center

    Sylmar, California

  • Kaiser Permanente Oncology Clinical Trials

    Vallejo, California

  • USOR: Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Florida Cancer Specialist South Division

    Fort Myers, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • Women's Care Florida / Women's Cancer Associates

    St. Petersburg, Florida

  • Florida Cancer Specialist North Division

    St. Petersburg, Florida

  • Florida Cancer Specialists

    Tallahassee, Florida

  • Florida Cancer Specialist East Division

    West Palm Beach, Florida

  • Memorial University Medical Center

    Savannah, Georgia

  • Hawaii Pacific Health - Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • University of Chicago

    Chicago, Illinois

  • Dr. Sudarshan K. Sharma, Ltd.

    Hinsdale, Illinois

  • Community Health Network

    Indianapolis, Indiana

  • University of Kansas Cancer Center

    Westwood, Kansas

  • St. Elizabeth Healthcare

    Edgewood, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Ochnser Medical Center Jefferson

    New Orleans, Louisiana

  • WK Physicians Network/Gynecologic Oncology Associates

    Shreveport, Louisiana

  • Holy Cross Hospital

    Silver Spring, Maryland

  • USOR: Maryland Oncology Hematology, P.A.

    Silver Spring, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Baystate Medical Center

    Springfield, Massachusetts

  • University of Massachusetts

    Worcester, Massachusetts

  • St. Joseph Mercy Hospital

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • USOR: Minnesota Oncology Hematology, PA

    Woodbury, Minnesota

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.